Clinical Trial Update: Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) [Phase 3]

View source ↗

Summary

Phase 3 trial investigating lenvatinib combined with transarterial chemoembolization (TACE) and camrelizumab for conversion to resection in advanced hepatocellu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Camrelizumab (camrelizumab)
• Lenvatinib (lenvatinib)

Snippet

Sponsor: Wen Tianfu | Conditions: Advanced Hepatocellular Carcinoma | Phase 3 | Status: RECRUITING